Abstract
We report the discovery of three polymorphs of the very recently FDA-approved boron-containing active pharmaceutical ingredient, Crisaborole. Crisaborole displays polymorphism based on the syn (Form I) and anti (Form II) conformations of the hydroxyl group of the oxaborole ring as shown by single-crystal X-ray analysis. Forms I and II were discovered based on the availability from two different commercial suppliers, while Form III was obtained upon heating of Form I or II. A cocrystal based on 4,4′-bipyridine was also obtained.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
